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Ashley Shafferman1, James D Birmingham2 and Randy Q Cron3*Abstract
We report an 11-week-old female who presented with Kawasaki disease (KD) complicated by macrophage activation
syndrome (MAS). The infant presented to the hospital with persistent fever, cough, diarrhea, and emesis, among other
symptoms. Her condition quickly began to decompensate, and she developed classic features (conjunctivitis, rash,
cracked lips, distal extremity edema) prompting a diagnosis of acute KD. The patient was treated with standard therapy
for KD including three doses of intravenous immunoglobulin (IVIG), aspirin, and high dose glucocorticoids with no
change in her condition. Due to a high suspicion for MAS, high dose anakinra therapy was initiated resulting in
dramatic clinical improvements. She also received one dose of infliximab for concern for coronary artery changes,
and over the course of several months, anakinra and high dose glucocorticoids were tapered. Nearly complete reversal
of echocardiogram changes were observed after 8 months, and the infant is now off all immunosuppressive therapy.
In this case report, we briefly review the importance of early recognition of MAS in pediatric patient populations with
rheumatic diseases, and we suggest early initiation of anakinra therapy as a rapid and effective treatment option.
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Kawasaki disease (KD), a condition of unknown etiology,
is one of the most common acute inflammatory vasculit-
ides in children and infants. Diagnosis of KD is based on
clinical findings, resulting from diffuse inflammation of
small and medium sized vessels. The most common acute
inflammatory manifestations in KD include fever, bilateral
nonexudative conjunctival injection, erythema of oral mu-
cosa, peripheral edema, polymorphous rash, and cervical
lymphadenopathy [1]. Though no specific laboratory test
exists for the diagnosis of KD, laboratory studies reveal
typical findings, including: leukocytosis with neutrophilia,
elevated erythrocyte sedimentation rate (ESR), elevated C-
reactive protein (CRP), normocytic anemia, hyponatremia,
hypoalbuminemia, and thrombocytosis [1,2]. Less com-
monly seen but associated with KD are elevated transami-
nases (30%), mild hyperbilirunemia (10%), and sterile pyruia
(33%) [3,4]. Early identification and initiation of treatment
is critical in improving the outcome of KD. Approximately* Correspondence: rcron@peds.uab.edu
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article, unless otherwise stated.15-25% of children left untreated, or with a severe delay in
treatment, develop coronary artery aneurysms, which can
lead to myocardial ischemia, infarction, and death [5]. Ini-
tial treatment of KD involves administration of high dose
intravenous immunoglobulin (IVIG) and aspirin. In cases
of refractory KD, retreatment with IVIG, corticosteroids,
or infliximab, a tumor necrosis factor inhibitor (TNF-i),
have been shown to be effective treatment [1,6,7].
A life threatening complication of KD that may easily
remain undiagnosed is macrophage activation syndrome
(MAS), also known as secondary hemophagocytic lym-
phohistiocytosis (HLH). Though the pathophysiology is
not completely understood, it is thought that MAS re-
sults from an uncontrolled immune response to certain
immunologic stressors such as infections, malignancies,
and autoimmune or autoinflammatory states. Undiag-
nosed and untreated, MAS results in a systemic inflam-
matory reaction characterized by excessive cytokine
production, activation of macrophages, and hemophago-
cytosis. Patients diagnosed with MAS have been shown
to exhibit decreased natural killer (NK) cell number and
function [8-11].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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tory findings of acute KD, including fever, rash, and
elevated transaminases, are shared with MAS, it can be
difficult to distinguish between the two processes and
requires a high degree of suspicion for diagnosis [1,8].
An important, available, timely, and affordable diagnostic
marker of MAS is an elevated serum ferritin level. Other
laboratory values highly characteristic of MAS include
elevated triglycerides, elevated liver enzymes, and de-
creased fibrinogen [12]. In a retrospective review of 638
children with acute KD, the 12 (1.9%) children found to
also have a diagnosis of MAS all exhibited hyperferritine-
mia. Hypofibrinoginemia, cytopenia in 2 or more cell lines,
hypertriglyceridemia, and hepatosplenomegaly were seen in
11 of the 12 children with concomitant MAS. Treatment
beyond the standard protocol for acute KD, IVIG and as-
pirin, was required in all children except 1 [13]. Recently,
several case reports have successfully demonstrated the
use of the interleukin-1 (IL-1) receptor antagonist, ana-
kinra, in the treatment of KD (1-2 mg/kg/day) compli-
cated by MAS, as well as other pediatric and adult
diseases complicated by MAS [14-18]. In this case presen-
tation, we report the use of high dose (9 mg/kg/day) ana-
kinra in the treatment of severe neonatal KD complicated
by MAS.
Case presentation
An 11-week-old Caucasian female fraternal twin, from
non-consanguineous parents who were not from a genet-
ically isolated population, presented to the hospital with
two days duration of cough, congestion, rhinorrhea, diar-
rhea, emesis, decreased oral intake, reduced urine output,
and fever of 103 °F. She was admitted for dehydration and
begun on IV fluids. Initial laboratory studies revealed
neutrophilia, anemia, normal platelet count, hyponatre-
mia, and mild hyperbilirubinemia (Table 1). Urine studies
revealed sterile pyuria, and blood cultures were reassur-
ingly negative after 48 hours. Work up for CMV, HHV8,
parvovirus B19, adenovirus, and HSV infections were all
negative.
On hospital day 3, the infant developed a diffuse,
erythematous, macular-papular blanching rash on the face,
trunk, and extremities. She was also noted to have periph-
eral edema, non-purulent injected bilateral conjunctiva,
dry and cracked desquamating rash on her lips and eyelids,
mild hepatomegaly, and a few small (<1 cm) bilateral
cervical lymph nodes. Progressive respiratory distress
developed requiring intubation. Repeat laboratory studies
showed persistent neutrophilia, worsening anemia, new on-
set thrombocytopenia, normal transaminases, mild hypo-
natremia, hypoalbuminemia, and elevated acute phase
reactants (Table 1). A cerebral spinal fluid (CSF) analysis re-
vealed pleocytosis with mononuclear cell predominance, nor-
mal glucose, and mildly elevated protein. An echocardiogramshowed a right coronary artery diameter at the upper
limits of normal with no evidence of aneurysm. Due to a
high suspicion for KD, an abdominal ultrasound was per-
formed showing hydrops of the gallbladder with circum-
ferential edematous thickening of the gallbladder wall,
further supporting the clinical diagnosis. The patient was
subsequently started on aspirin and 2 g/kg IVIG on days
3, 4, and 6 of hospitalization (Table 1). Echocardiogram of
the coronary arteries on day 4, revealed the following
measurements and associated Z-scores: 0.16 cm (Z - 0.91),
0.17 cm (Z – 1.4), and 0.19 cm (Z – 0.25) for the left
anterior descending (LAD), right (RCA), and left main
(LM) coronary arteries, respectively.
On day 6 of hospitalization, flow cytometry was
obtained due to concern for MAS (elevated ferritin and
thrombocytopenia). Results revealed few NK cells (<1%)
and decreased CD8 T cells compared to the reference
range for age making it difficult to analyze cytolytic
function; however, there were normal perforin and
granzyme B levels in both cell lines. Genetic analyses
detected no mutations in familial HLH genes (STXBP2,
STX11, MUNC13-4, RAB27A). Subsequently, the pa-
tient was given a three-day course of high-dose methyl-
prednisolone, 30 mg/kg/dose. Despite treatment with
IVIG and methylprednisolone, the patient’s conditioned
remained unchanged. A repeat echocardiogram was
obtained revealing that the right coronary artery and the
left anterior descending artery were mildly dilated, and
the left main coronary artery was at the upper limits of
normal, all significantly larger than on the initial echo-
cardiogram four days prior. The infant was started on
therapy with high dose anakinra (3 mg/kg/dose, twice
daily for 3 days, then increased to three times a day for
rash and rise in CRP). There was an immediate reduc-
tion noted in pulmonary resistance by mechanical venti-
lation, and she stabilized in terms of her vital signs. By
day 3 of treatment the patient was displaying a dramatic
improvement in her rash and an impressive reduction in
her overall inflamed appearance, as well as decreased
levels of CRP and an increasing platelet count (Table 1).
A second rise in ferritin occurred despite a remarkable
rise in platelet count and fall in CRP coincident with
anakinra treatment. Perhaps this was a reflection of liver
and bone marrow recovery as she dramatically improved
clinically.
Despite noted clinical improvements with the use of
anakinra and methylprednisolone, a third echocardiogram
revealed interval diffuse enlargement of the entire coronary
artery system [LAD – 0.36 cm (Z – 11), RCA – 0.32 cm
(Z – 6.5), LM – 0.37 cm (Z – 5.6)] without discrete
aneurysms. Due to concerns about progressive coronary
changes, therapy was supplemented with one dose of
infliximab (5 mg/kg) and increased methylprednisolone
(4 mg/kg/dose, three times a day). The patient remained



















































3 133.4 40 6.9 12.12 59 32 25 18 138
Serum sodium 131 mEq/L
Hypoalbuminemia of
1.8 g/dL (reference range:
3.4-5.4 g/dL) IVIG dose #1
4 10.1 16.8 121 24 19 82 801 IVIG dose #2/Transfusion
6 191.6 24 9.9 27.5 66 22 17 239 255
IVIG dose#3
Methylprednisolone
30 mg/kg × 3 days Flow
cytometry
7 234.1 113 8.2 16.6 52 273 207
Anakinra started
(3 mg/kg BID) (increased
to 3 mg/kg TID after
3 days)
8 122.9 64 7.8 21.5 133 16 14 213
Slight clinical
improvement
9 65 37 12.7 22.6 156 165
Methylprednisolone




12 98.3 67 13.2 19.6 607 32 21 288 574
Echocardiogram: diffuse
enlargement of the entire
coronary artery system
Infliximab 5 mg/kg ×1
Methylprednisolone
increased (4 mg/kg TID)
16 1.6 25 11.3 12.9 963 27 28 201 239 700 108
Methylprednisolone
decreased (2 mg/kg TID)
20 0.3 5 13 20.9 972 269 212 754 134
Methylprednisolone
decreased (2 mg/kg Daily)





started 1.5 mg/kg Daily
(tapered over 10 days)
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; Hb: hemoglobin; WBC: white blood count; PLTs: platelets; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase;
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(1.5 mg/kg/day) over the 10 days following discharge,
and then off anakinra (8 mg/kg/day, divided twice daily)
slowly over the next 5 months. A repeat flow cytometry
study, approximately 6 months after initial laboratory
studies, revealed reduced perforin and granzyme B in
CD8 T cells, normal perforin and granzyme B in NK
cells, and normal absolute levels of both CD8 T cells
and NK cells. An echocardiogram 8 months after initial
coronary artery changes revealed normal coronary
artery origins, with only mild dilation of the proximal
right coronary artery, and a left main coronary artery at the
upper limits of normal in size [LAD – 0.18 cm (Z – 0.84),
RCA – 0. 24 cm (Z – 2.8), LM – 0.26 cm (Z – 1.6)]. The
patient is now off all immune suppressive therapy and is
maintained on low dose aspirin and propranolol, with
regular follow-up appointments with her cardiologist and
rheumatologist.
Discussion
Our case highlights the importance of anakinra, an IL-1
receptor antagonist, in children with KD complicated by
MAS. Our patient was rather young for typical KD and
may not be universally representative, but she did meet
KD criteria and had evidence of coronary artery abnor-
malities. Although our patient did not have sCD25 mea-
sured and did not meet restrictive familial HLH criteria,
she had a >88% chance of having reactive HLH/MAS as
per the newly developed HScore [19]. Though only 1.9%
of children with acute KD are reported to develop overt
MAS, it is unclear whether there is a greater percentage
with subclinical MAS as in children with systemic juven-
ile idiopathic arthritis (sJIA) [13,20]. It is also unknown
whether KD complicated by MAS is being labeled as
Kawasaki shock syndrome (7% of KD patients studied),
refractory KD, or recurrent KD, as the processes may ap-
pear to have similar clinical features [21,22]. At present
it is unclear whether Kawasaki shock syndrome is on the
MAS spectrum or whether a subset of children with
Kawasaki shock syndrome have frank MAS. Recently, a
retrospective survey was conducted in Korea to deter-
mine differentiating factors between recurrent KD and
KD complicated by MAS. The study concluded that the
most important distinguishing factor was the time
course of symptoms and signs. The onset of MAS follow-
ing KD was approximately 13.3 days (range, 3–22 days);
however, recurrent KD typically occurred much later at a
mean of 17.9 months (range, 1–60 months) [21].
It is critically important to identify MAS early, as the
potentially devastating complication carries a high mor-
tality rate and may require a more aggressive treatment
approach than the traditional treatment protocol for KD
[23]. The initial treatment strategy for MAS involves
supportive therapy and aggressive immunosuppressivetreatment to reduce the severe systemic inflammation,
which causes the life threatening symptoms. While it is
highly important to control hyperinflammation, sup-
pressing the patient’s remaining immune system can also
pose significant risks. Traditionally, immunosuppressive
therapies used in the treatment of MAS include IVIG,
high dose glucocorticoids, and cyclosporine [24]. Etopo-
side has also been suggested for treatment of MAS but
carries high morbidity and mortality rates [25].
As an alternative to traditional therapy for MAS, we
suggest a more targeted therapy with anakinra as an
effective and rapid treatment for MAS in children and
very young infants. Additionally, our case presentation
demonstrates that anakinra used with infliximab can be
an effective combination therapy in treating MAS and
KD associated complications. Several case reports have
shown successful use of the IL-1 receptor antagonist,
anakinra, in treating children with various rheumatologic
conditions complicated by MAS [14-16]. In addition to
treating a case of KD associated MAS [15], low dose
(1-2 mg/kg/day) anakinra has also been shown to success-
fully treat refractory KD [26]. Because infants with autoin-
flammatory disorders [27] and cases of severe MAS may
require higher dosing of anakinra [14], it may be prudent
to treat with higher doses of anakinra until the inflamma-
tion can be controlled. Recently, a retrospective case series
demonstrated the therapeutic role of anakinra in 8 chil-
dren in the intensive care unit that were diagnosed with
secondary HLH or MAS. The study showed promising
results with dramatic decreases in ferritin, fibrinogen, and
CRP levels following initiation of anakinra. Importantly,
no infections were attributed to the use of anakinra [18].
Infliximab may also play a role in lowering inflammation
in KD and potentially reducing coronary artery abnormal-
ities [28,29].Conclusions
It appears that early intervention with high dose anakinra
may provide a safe and effective alternative to treatment
of life-threatening MAS in children. As further knowledge
of MAS, or secondary HLH, comes to the forefront, it is
imperative to consider this diagnosis in critically ill chil-
dren, especially those with underlying rheumatic condi-
tions. Further study of anakinra in the treatment of MAS,
as well as combination therapy of anakinra and infliximab,
as a therapeutic alternative in KD associated MAS with
coronary artery dilation is warranted.Consent
Written informed consent was obtained from the pa-
tient’s parents for publication of this Case Report. A copy
of the written consent is available for review by the
Editor-in-Chief of this journal.
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